COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Protocol No
GENMAB-GCT3014-01
Principal Investigator
Binod Dhakal
Phase
I/II
Summary
This project is being done to find out if GEN3104 (HexaBody®-CD38) is safe in patients with multiple myeloma or acute myeloid leukemia or other types of blood cancers.
Description
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL